Table 1. Baseline patients and tumor characteristics.
| Variables | n (%) |
| Demographics | |
| Total number of patients | 101 |
| Age at baseline | |
| <65 years | 72 (71) |
| ≥65 years | 29 (29) |
| Sex | |
| Male | 76 (75) |
| Female | 25 (25) |
| Vital status at time of analysis | |
| Alive | 23 (22) |
| Deceased | 78 (78) |
| Follow-up time in months | |
| Mean (range) | 17.1 (0.1-140.4) |
| Median (interquartile range) | 10.8 (4.0-20.7) |
| Etiology | |
| Hepatitis B virus | 16 (16) |
| Hepatitis C virus | 45 (45) |
| Hepatitis B virus+hepatitis C virus | 2 (2) |
| Human immunodeficiency virus | 5 (5) |
| Alcohol | 35 (35) |
| Non-alcoholic steatohepatitis | 7 (7) |
| Cryptogenic | 7 (7) |
| Cirrhosis | 36 (36) |
| Ethnicity | |
| White | 65 (64) |
| African American | 16 (16) |
| Hispanic | 1 (1) |
| Other | 8 (8) |
| Unknown | 11 (11) |
| Barcelona Clinic Liver Cancer stage | |
| B | 29 (29) |
| C | 69 (68) |
| D | 3 (3) |
| Child-Pugh class | |
| A | 68 (67) |
| B | 32 (32) |
| C | 1 (1) |
| ECOG performance score | |
| 0 | 56 (55) |
| 1 | 39 (39) |
| 2 | 4 (4) |
| 3 | 2 (2) |
| Tumor characteristics | |
| Number of lesions | |
| 1 | 18 (18) |
| 2 | 19 (19) |
| 3 | 11 (11) |
| 4 or more | 53 (52) |
| Tumor size in cm | |
| Mean (range) | 8.6 (1.5-19.5) |
| Median (interquartile range) | 8.0 (5.0-11.5) |
| Portal invasion | |
| Yes | 42 (42) |
| No | 59 (58) |
| Extrahepatic invasion | |
| Yes | 22 (22) |
| No | 79 (78) |
| TACE type | |
| Lipiodol® | 67 (66) |
| Drug-eluting beads | 34 (34) |
| Number of TACE sessions | |
| 1 | 48 (48) |
| 2 | 19 (18) |
| 3 | 13 (13) |
| 4 or more | 21 (21) |